A healthy investment in healthier futures.
Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cryo-Cell Reports Fiscal Second Quarter 2017 Financial Results
Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2017.
Read More
Cryo-Cell Reports Fiscal First Quarter 2017 Financial Results
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2017.
Read More
Cryo-Cell Reports Financial Results for Fiscal 2016
Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year 2016.
Read More
Cryo-Cell Reports Fiscal Third Quarter 2016 Results
OLDSMAR, Fla. – October 18, 2016 – Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2016.
Financial Results
Revenue
Consolidated revenues for the third quarter of fiscal 2016 were $6.3 million compared to $5.4 million for the third quarter of fiscal 2015. The revenues for the third quarter of fiscal 2016 consisted of $5.6 million in processing and storage fees, $609,000 in licensee income, and $88,000 in product revenue, compared to $5.0 million in processing and storage fees, $169,000 in licensee income and $266,000 in product revenue for the third quarter of fiscal 2015.
Read More
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2016 Financial Results
OLDSMAR, Fla. – July 11, 2016 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2016.
Financial Results
Revenue
Consolidated revenues for the second quarter of fiscal 2016 were $5.8 million compared to $5.0 million for the second quarter of fiscal 2015. The revenues for the 2016 quarter consisted of $5.3 million in processing and storage fee revenue, $357,000 in licensee and royalty income and $66,000 in product revenue compared to $4.8 million in processing and storage fee revenue, $169,000 in licensee and royalty income and no product revenue for the 2015 quarter.
Read More